ATE91628T1 - Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten. - Google Patents

Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.

Info

Publication number
ATE91628T1
ATE91628T1 AT89115252T AT89115252T ATE91628T1 AT E91628 T1 ATE91628 T1 AT E91628T1 AT 89115252 T AT89115252 T AT 89115252T AT 89115252 T AT89115252 T AT 89115252T AT E91628 T1 ATE91628 T1 AT E91628T1
Authority
AT
Austria
Prior art keywords
growth factor
fibroblast growth
acid
treatment
gastrointestinal diseases
Prior art date
Application number
AT89115252T
Other languages
English (en)
Inventor
Moses Judah Folkman
Koichi Kato
Original Assignee
Takeda Chemical Industries Ltd
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Childrens Medical Center filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE91628T1 publication Critical patent/ATE91628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT89115252T 1988-08-19 1989-08-18 Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten. ATE91628T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23496688A 1988-08-19 1988-08-19
US07/382,263 US5175147A (en) 1988-08-19 1989-07-20 Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
EP89115252A EP0360006B1 (de) 1988-08-19 1989-08-18 Sauerwiderstehender Fibroblast-Wachstumsfaktor, Zubereitung zur Behandlung von Magen-Darmweg-Geschwürkrankheiten

Publications (1)

Publication Number Publication Date
ATE91628T1 true ATE91628T1 (de) 1993-08-15

Family

ID=26928432

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89115252T ATE91628T1 (de) 1988-08-19 1989-08-18 Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.

Country Status (16)

Country Link
US (2) US5175147A (de)
EP (1) EP0360006B1 (de)
JP (1) JP2501480B2 (de)
KR (1) KR920700040A (de)
CN (1) CN1040741A (de)
AT (1) ATE91628T1 (de)
CA (1) CA1330757C (de)
DE (1) DE68907679T2 (de)
DK (1) DK93890A (de)
ES (1) ES2058423T3 (de)
FI (2) FI901949A0 (de)
HU (1) HU207227B (de)
IE (1) IE63046B1 (de)
IL (1) IL91322A (de)
NO (1) NO901710D0 (de)
WO (1) WO1990001941A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
EP0406738A3 (en) * 1989-07-03 1991-08-14 Takeda Chemical Industries, Ltd. Production of acidic fgf protein
JPH0343088A (ja) * 1989-09-29 1991-02-25 Takeda Chem Ind Ltd ａＦＧＦ蛋白質の製造法
CA2020720A1 (en) * 1989-07-13 1991-01-14 Shigeko Yamazaki Method for the purification of therapeutically active recombinant acidic fibroblast growth factor
AUPN271295A0 (en) * 1995-05-02 1995-05-25 Gropep Pty Ltd Method of treatment
US6399569B1 (en) 1991-03-11 2002-06-04 Curis, Inc. Morphogen treatments for limiting proliferation of epithelial cells
US5972884A (en) * 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
WO1992018153A1 (en) * 1991-04-12 1992-10-29 Creative Biomolecules, Inc. Method of treating gastrointestinal ulcers with platelet derived growth factor
MX9201801A (es) * 1991-04-16 1992-10-30 Seikagaku Kogyo Co Ltd Oligosacarido que tiene afinidad para el factor de desarrollo del fibroplasto y procedimiento para producirlo.
US6190864B1 (en) * 1991-05-08 2001-02-20 Chiron Corporation HCV genomic sequences for diagnostics and therapeutics
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
US5916772A (en) * 1992-06-16 1999-06-29 Whittier Institute For Diabetes And Endocrinology Recombinant production of saporin-containing proteins
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
FR2718023B1 (fr) * 1994-03-30 1996-08-14 Paris Val Marne Universite Médicament et composition pharmaceutique pour le traitement de lésions du tractus digestif.
US5783568A (en) * 1994-06-10 1998-07-21 Sugen, Inc. Methods for treating cancer and other cell proliferative diseases
US5531880A (en) * 1994-09-13 1996-07-02 Microelectronics And Computer Technology Corporation Method for producing thin, uniform powder phosphor for display screens
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
EP1309604B1 (de) * 2000-08-15 2007-03-28 Phage Biotechnology Corporation Phagen-abhängige superproduktion biologisch aktiver proteine und peptide
AU2001286996A1 (en) * 2000-08-31 2002-03-13 Chiron Corporation Stabilized fgf formulations containing reducing agents
BR0207297A (pt) 2001-02-15 2005-04-19 King Pharmaceuticals Inc Composição farmacêutica em forma sólida e método de preparar uma forma de dosagem sólida de um ingrediente farmaceuticamente ativo
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
CA3091215A1 (en) * 2018-02-13 2019-08-22 University Of Florida Research Foundation Fibroblast growth factor analogs and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296100A (en) * 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3382562D1 (de) * 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
JPS6034997A (ja) * 1983-05-09 1985-02-22 ジヨージ、ジヨセフ、トダロ 生物学的活性ポリペプチド類
JPS6028999A (ja) * 1983-06-30 1985-02-14 Maruho Kk 細胞増殖促進作用を有するたんぱく質、その組成物と製造方法
US4745098A (en) * 1984-02-24 1988-05-17 The Regents Of The University Of California Compositions and method for improving wound healing
CA1207239A (en) * 1984-08-10 1986-07-08 Upendra K. Banik Gastrointestinal compositions
JPS6172947A (ja) * 1984-09-18 1986-04-15 Takasago Thermal Eng Co Ltd クリ−ンル−ムの形成法およびこの方法に使用する空気調和設備ユニツト
DE3689845T3 (de) * 1985-09-12 2001-11-15 Scios Inc., Sunnyvale Rekombinanter fibroblast-wachstumsfaktor.
DK122687A (da) * 1986-03-14 1987-09-15 Takeda Chemical Industries Ltd Polypeptid, dna og anvendelse deraf
CA1294546C (en) * 1986-04-23 1992-01-21 John S. Sundsmo Wound healing composition containing collagen
NZ220917A (en) * 1986-07-11 1991-05-28 Merck & Co Inc Human and bovine acidic fibroblast growth factor vectors, hosts and compositions
AU1185488A (en) * 1987-01-16 1988-08-10 Amgen, Inc. Production of fibroblast growth factor
EP0298723A1 (de) * 1987-07-07 1989-01-11 California Biotechnology, Inc. Rekombinante Fibroblasten-Wachstumsfaktoren
KR890701607A (ko) * 1987-11-24 1989-12-21 원본미기재 섬유아세포 성장 인자의 유사체
AU614137B2 (en) * 1988-06-06 1991-08-22 Takeda Chemical Industries Ltd. Stabilized fgf composition and production thereof
JPH0240399A (ja) * 1988-07-27 1990-02-09 Takeda Chem Ind Ltd 線維芽細胞増殖因子ムテインの複合体あるいは組成物

Also Published As

Publication number Publication date
KR920700040A (ko) 1992-02-19
WO1990001941A1 (en) 1990-03-08
DK93890D0 (da) 1990-04-17
FI943028A7 (fi) 1994-06-22
IL91322A0 (en) 1990-03-19
EP0360006B1 (de) 1993-07-21
JP2501480B2 (ja) 1996-05-29
FI943028L (fi) 1994-06-22
CA1330757C (en) 1994-07-19
NO901710L (no) 1990-04-18
CN1040741A (zh) 1990-03-28
DE68907679T2 (de) 1994-01-27
US5175147A (en) 1992-12-29
JPH03505736A (ja) 1991-12-12
FI901949A7 (fi) 1990-04-18
AU4218989A (en) 1990-03-23
HU207227B (en) 1993-03-29
NO901710D0 (no) 1990-04-18
EP0360006A3 (en) 1990-04-04
FI943028A0 (fi) 1994-06-22
HU895785D0 (en) 1990-12-28
DE68907679D1 (de) 1993-08-26
IL91322A (en) 1994-12-29
US5401721A (en) 1995-03-28
FI901949A0 (fi) 1990-04-18
IE892664L (en) 1990-02-19
ES2058423T3 (es) 1994-11-01
IE63046B1 (en) 1995-03-22
HUT55638A (en) 1991-06-28
DK93890A (da) 1990-04-17
AU630111B2 (en) 1992-10-22
EP0360006A2 (de) 1990-03-28

Similar Documents

Publication Publication Date Title
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ATE81978T1 (de) Verwendung von 3'-azido-3'-deoxythymidin zur behandlung oder vorbeugung von menschlichen retrovirus-infektionen.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3785388D1 (de) Antivirale peptide und mittel zur behandlung von herpes.
DE3884200D1 (de) Verfahren zur Behandlung von Mastitis und anderen Staphylokokkeninfektionen.
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
ATE126056T1 (de) Mittel zur behandlung von seniler demenz, gedächtnisstörungen und ähnlichen zuständen.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
DE3851971D1 (de) Verwendung antigener Substanzen zur Prophylaxe oder Therapie von Störungen und Krankheiten im Verdauungstrakt von Tieren und Menschen.
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
DE3686019D1 (de) Die verwendung von nitrofurantoin zur behandlung und verhuetung von magen-darmkrankheiten.
DE69328307D1 (de) Kombination von atovaquone mit proguanil zur behandlung von protozoeninfektion
HUP9903688A2 (hu) Olanzapin alkalmazása az autizmus kezelésére szolgáló gyógyszerkészítmény előállítására
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
DE3668116D1 (de) Zusammensetzung zur behandlung von infektionen.
ATE136463T1 (de) Verwendung von 1,2,3,4-tetrahydroacridinen zur behandlung von aids, sowie verbindungen
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
DE68914886D1 (de) Mittel zur Behandlung von Raynaud's Krankheit.
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
NO912528D0 (no) Behandling av sykdommer forbundet med jodmangel.
ATE92761T1 (de) Lang haltende zusammensetzung von propafenon und chinidin zur behandlung des zustandes des herzens.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee